Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the “Dx Company”). Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers serving addiction treatment, pain management, and behavioral health. The Dx Company’s 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million.
Read the full article: Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company //
Source: https://www.globenewswire.com/news-release/2026/07/27/3333332/0/en/profusa-announces-key-management-changes-and-signing-of-non-binding-term-sheet-for-the-acquisition-of-a-commercial-stage-diagnostics-company.html?_gl=1*1ki1drk*_up*MQ..*_ga*MjAwODM3MTExNS4xNzg1MTUxMTE0*_ga_B6167QB2TF*czE3ODUxNTExMTMkbzEkZzAkdDE3ODUxNTExMTMkajYwJGwwJGg0ODU4ODU1OA..*_ga_ERWPGTJ5X8*czE3ODUxNTExMTMkbzEkZzAkdDE3ODUxNTExMTMkajYwJGwwJGgw